Cargando…

Development and Validation of a Computational Model for Androgen Receptor Activity

[Image: see text] Testing thousands of chemicals to identify potential androgen receptor (AR) agonists or antagonists would cost millions of dollars and take decades to complete using current validated methods. High-throughput in vitro screening (HTS) and computational toxicology approaches can more...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleinstreuer, Nicole C., Ceger, Patricia, Watt, Eric D., Martin, Matthew, Houck, Keith, Browne, Patience, Thomas, Russell S., Casey, Warren M., Dix, David J., Allen, David, Sakamuru, Srilatha, Xia, Menghang, Huang, Ruili, Judson, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2016
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396026/
https://www.ncbi.nlm.nih.gov/pubmed/27933809
http://dx.doi.org/10.1021/acs.chemrestox.6b00347
_version_ 1783229990513410048
author Kleinstreuer, Nicole C.
Ceger, Patricia
Watt, Eric D.
Martin, Matthew
Houck, Keith
Browne, Patience
Thomas, Russell S.
Casey, Warren M.
Dix, David J.
Allen, David
Sakamuru, Srilatha
Xia, Menghang
Huang, Ruili
Judson, Richard
author_facet Kleinstreuer, Nicole C.
Ceger, Patricia
Watt, Eric D.
Martin, Matthew
Houck, Keith
Browne, Patience
Thomas, Russell S.
Casey, Warren M.
Dix, David J.
Allen, David
Sakamuru, Srilatha
Xia, Menghang
Huang, Ruili
Judson, Richard
author_sort Kleinstreuer, Nicole C.
collection PubMed
description [Image: see text] Testing thousands of chemicals to identify potential androgen receptor (AR) agonists or antagonists would cost millions of dollars and take decades to complete using current validated methods. High-throughput in vitro screening (HTS) and computational toxicology approaches can more rapidly and inexpensively identify potential androgen-active chemicals. We integrated 11 HTS ToxCast/Tox21 in vitro assays into a computational network model to distinguish true AR pathway activity from technology-specific assay interference. The in vitro HTS assays probed perturbations of the AR pathway at multiple points (receptor binding, coregulator recruitment, gene transcription, and protein production) and multiple cell types. Confirmatory in vitro antagonist assay data and cytotoxicity information were used as additional flags for potential nonspecific activity. Validating such alternative testing strategies requires high-quality reference data. We compiled 158 putative androgen-active and -inactive chemicals from a combination of international test method validation efforts and semiautomated systematic literature reviews. Detailed in vitro assay information and results were compiled into a single database using a standardized ontology. Reference chemical concentrations that activated or inhibited AR pathway activity were identified to establish a range of potencies with reproducible reference chemical results. Comparison with existing Tier 1 AR binding data from the U.S. EPA Endocrine Disruptor Screening Program revealed that the model identified binders at relevant test concentrations (<100 μM) and was more sensitive to antagonist activity. The AR pathway model based on the ToxCast/Tox21 assays had balanced accuracies of 95.2% for agonist (n = 29) and 97.5% for antagonist (n = 28) reference chemicals. Out of 1855 chemicals screened in the AR pathway model, 220 chemicals demonstrated AR agonist or antagonist activity and an additional 174 chemicals were predicted to have potential weak AR pathway activity.
format Online
Article
Text
id pubmed-5396026
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-53960262017-04-20 Development and Validation of a Computational Model for Androgen Receptor Activity Kleinstreuer, Nicole C. Ceger, Patricia Watt, Eric D. Martin, Matthew Houck, Keith Browne, Patience Thomas, Russell S. Casey, Warren M. Dix, David J. Allen, David Sakamuru, Srilatha Xia, Menghang Huang, Ruili Judson, Richard Chem Res Toxicol [Image: see text] Testing thousands of chemicals to identify potential androgen receptor (AR) agonists or antagonists would cost millions of dollars and take decades to complete using current validated methods. High-throughput in vitro screening (HTS) and computational toxicology approaches can more rapidly and inexpensively identify potential androgen-active chemicals. We integrated 11 HTS ToxCast/Tox21 in vitro assays into a computational network model to distinguish true AR pathway activity from technology-specific assay interference. The in vitro HTS assays probed perturbations of the AR pathway at multiple points (receptor binding, coregulator recruitment, gene transcription, and protein production) and multiple cell types. Confirmatory in vitro antagonist assay data and cytotoxicity information were used as additional flags for potential nonspecific activity. Validating such alternative testing strategies requires high-quality reference data. We compiled 158 putative androgen-active and -inactive chemicals from a combination of international test method validation efforts and semiautomated systematic literature reviews. Detailed in vitro assay information and results were compiled into a single database using a standardized ontology. Reference chemical concentrations that activated or inhibited AR pathway activity were identified to establish a range of potencies with reproducible reference chemical results. Comparison with existing Tier 1 AR binding data from the U.S. EPA Endocrine Disruptor Screening Program revealed that the model identified binders at relevant test concentrations (<100 μM) and was more sensitive to antagonist activity. The AR pathway model based on the ToxCast/Tox21 assays had balanced accuracies of 95.2% for agonist (n = 29) and 97.5% for antagonist (n = 28) reference chemicals. Out of 1855 chemicals screened in the AR pathway model, 220 chemicals demonstrated AR agonist or antagonist activity and an additional 174 chemicals were predicted to have potential weak AR pathway activity. American Chemical Society 2016-11-18 2017-04-17 /pmc/articles/PMC5396026/ /pubmed/27933809 http://dx.doi.org/10.1021/acs.chemrestox.6b00347 Text en Copyright © 2016 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Kleinstreuer, Nicole C.
Ceger, Patricia
Watt, Eric D.
Martin, Matthew
Houck, Keith
Browne, Patience
Thomas, Russell S.
Casey, Warren M.
Dix, David J.
Allen, David
Sakamuru, Srilatha
Xia, Menghang
Huang, Ruili
Judson, Richard
Development and Validation of a Computational Model for Androgen Receptor Activity
title Development and Validation of a Computational Model for Androgen Receptor Activity
title_full Development and Validation of a Computational Model for Androgen Receptor Activity
title_fullStr Development and Validation of a Computational Model for Androgen Receptor Activity
title_full_unstemmed Development and Validation of a Computational Model for Androgen Receptor Activity
title_short Development and Validation of a Computational Model for Androgen Receptor Activity
title_sort development and validation of a computational model for androgen receptor activity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396026/
https://www.ncbi.nlm.nih.gov/pubmed/27933809
http://dx.doi.org/10.1021/acs.chemrestox.6b00347
work_keys_str_mv AT kleinstreuernicolec developmentandvalidationofacomputationalmodelforandrogenreceptoractivity
AT cegerpatricia developmentandvalidationofacomputationalmodelforandrogenreceptoractivity
AT wattericd developmentandvalidationofacomputationalmodelforandrogenreceptoractivity
AT martinmatthew developmentandvalidationofacomputationalmodelforandrogenreceptoractivity
AT houckkeith developmentandvalidationofacomputationalmodelforandrogenreceptoractivity
AT brownepatience developmentandvalidationofacomputationalmodelforandrogenreceptoractivity
AT thomasrussells developmentandvalidationofacomputationalmodelforandrogenreceptoractivity
AT caseywarrenm developmentandvalidationofacomputationalmodelforandrogenreceptoractivity
AT dixdavidj developmentandvalidationofacomputationalmodelforandrogenreceptoractivity
AT allendavid developmentandvalidationofacomputationalmodelforandrogenreceptoractivity
AT sakamurusrilatha developmentandvalidationofacomputationalmodelforandrogenreceptoractivity
AT xiamenghang developmentandvalidationofacomputationalmodelforandrogenreceptoractivity
AT huangruili developmentandvalidationofacomputationalmodelforandrogenreceptoractivity
AT judsonrichard developmentandvalidationofacomputationalmodelforandrogenreceptoractivity